Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease.
Kayser
Steven R
SR
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, USA. skayser@itsa.ucsf.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics; D015195:Drug Design; D017850:Economics, Pharmaceutical; D005821:Genetic Techniques; D005820:Genetic Testing; D006801:Humans; D010347:Patient Care Planning; D018579:Patient Selection; D010597:Pharmacogenetics / Q000458:organization & administration*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors